Michael Schmidt's Stock Ratings

Guggenheim Analyst

Michael Schmidt is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

7.66%

Smart Score

58.5%

Overall Average Return Percentile

54th

Number of Ratings

40
Buy NowGet Alert
05/15/2024BOLTBuy Now
Bolt Biotherapeutics
$0.80——DowngradeBuy → NeutralGet Alert
04/30/2024DCPHBuy Now
Deciphera Pharmaceuticals
$25.50——DowngradeBuy → NeutralGet Alert
04/23/2024IMCRBuy Now
Immunocore Hldgs
$52.8374.14% → $92ReiteratesBuy → BuyGet Alert
04/15/2024IMNMBuy Now
Immunome
$13.88152.16% → $35Initiates → BuyGet Alert
04/05/2024ADCTBuy Now
ADC Therapeutics
$3.95——Reiterates → BuyGet Alert
03/28/2024ADCTBuy Now
ADC Therapeutics
$3.95178.38% → $11Initiates → BuyGet Alert
03/14/2024IMRXBuy Now
Immuneering
$1.47——DowngradeBuy → NeutralGet Alert
02/29/2024MRSNBuy Now
Mersana Therapeutics
$2.70159.26% → $7UpgradeNeutral → BuyGet Alert
02/27/2024BGNEBuy Now
BeiGene
$168.99104.15%$350 → $345MaintainsBuyGet Alert
01/05/2024ALLOBuy Now
Allogene Therapeutics
$2.83——DowngradeBuy → NeutralGet Alert
12/04/2023INCYBuy Now
Incyte
$57.17——UpgradeNeutral → BuyGet Alert
12/01/2023IMGNBuy Now
Immunogen
——$25 → $31DowngradeBuy → NeutralGet Alert
11/08/2023XNCRBuy Now
Xencor
$23.4644.94%$40 → $34MaintainsBuyGet Alert
10/11/2023EXELBuy Now
Exelixis
$20.9643.1% → $30ReiteratesBuy → BuyGet Alert
09/25/2023EXELBuy Now
Exelixis
$20.9643.1%$27 → $30MaintainsBuyGet Alert
07/25/2023SNDXBuy Now
Syndax Pharmaceuticals
$20.21107.82%$40 → $42MaintainsBuyGet Alert
07/24/2023MRTXBuy Now
Mirati Therapeutics
——$104 → $60MaintainsBuyGet Alert
07/11/2023SNDXBuy Now
Syndax Pharmaceuticals
$20.2197.92% → $40Initiates → BuyGet Alert
06/27/2023ACETBuy Now
Adicet Bio
$1.621134.57% → $20DowngradeBuy → NeutralGet Alert
06/15/2023MRSNBuy Now
Mersana Therapeutics
$2.70418.52% → $14Initiates → BuyGet Alert
05/23/2023BPMCBuy Now
Blueprint Medicines
$103.78-20.99%$78 → $82MaintainsBuyGet Alert
03/30/2023IMCRBuy Now
Immunocore Hldgs
$52.8360.89% → $85Initiates → BuyGet Alert
03/21/2023ORICBuy Now
ORIC Pharmaceuticals
$9.0465.93% → $15DowngradeBuy → NeutralGet Alert
02/28/2023SGENBuy Now
Seagen
—— → $170Reiterates → BuyGet Alert
02/28/2023BGNEBuy Now
BeiGene
$168.99107.11% → $350Reiterates → BuyGet Alert
01/20/2023BGNEBuy Now
BeiGene
$168.99107.11%$290 → $350MaintainsBuyGet Alert
01/12/2023ARVNBuy Now
Arvinas
$33.54——DowngradeBuy → NeutralGet Alert
01/04/2023DCPHBuy Now
Deciphera Pharmaceuticals
$25.50-13.72% → $22UpgradeNeutral → BuyGet Alert
01/03/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.10354.55% → $5UpgradeNeutral → BuyGet Alert
11/15/2022NLTXBuy Now
Neoleukin Therapeutics
———DowngradeBuy → NeutralGet Alert

Recent Analyst Stock Rating News

Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and nursing shortages impact both companies' performance and share value.
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Warren Buffett-Backed BYD Aims To Outperform Tesla, VW, Stellantis As Europe's Leading BEV Seller: 'The Long Term Is To Produce Locally;'
The company's strategy includes a budget model based on the Seagull, which sells in China for under $10,000.
Where Immunocore Hldgs Stands With Analysts
Evaluating BeiGene: Insights From 6 Financial Analysts
Analysts Just Upgraded These 4 REITs
4 Analysts Assess BeiGene: What You Need To Know
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
Beyond The Numbers: 4 Analysts Discuss PowerFleet Stock
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free